Colrain Capital LLC Has $10.45 Million Holdings in Medtronic PLC $MDT

Colrain Capital LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 26.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 132,354 shares of the medical technology company’s stock after purchasing an additional 27,404 shares during the quarter. Medtronic accounts for 3.5% of Colrain Capital LLC’s holdings, making the stock its 15th largest position. Colrain Capital LLC’s holdings in Medtronic were worth $10,449,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Anfield Capital Management LLC increased its stake in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Monetary Solutions Ltd acquired a new position in Medtronic in the 4th quarter valued at $27,000. Acumen Wealth Advisors LLC bought a new stake in shares of Medtronic during the 4th quarter valued at $29,000. Imprint Wealth LLC bought a new stake in shares of Medtronic during the 3rd quarter valued at $31,000. Finally, Basepoint Wealth LLC bought a new stake in shares of Medtronic during the 4th quarter valued at $32,000. 82.06% of the stock is currently owned by institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Bank of America issued a bullish outlook ahead of earnings. The firm sees continued momentum from one of Medtronic’s key growth businesses and believes an additional catalyst could develop, potentially improving investor expectations before the results. Bank of America makes bullish call on 77-year-old healthcare stock
• Positive Sentiment: Medtronic is one dividend increase away from Dividend King status. The company has raised its dividend for 49 consecutive years and currently pays $0.72 per quarter, or $2.88 annually. Reaching the 50-year milestone could reinforce MDT’s appeal to income-focused and defensive investors. Medtronic plc is Closing in on Dividend King Status
• Neutral Sentiment: BTIG reaffirmed its “Buy” rating but set a $91 price target, below MDT’s recent trading level. The recommendation supports the long-term outlook, while the target suggests limited near-term upside at current levels. Other recent analyst targets have been mixed, with a reported median of $101. BTIG reaffirms buy rating on Medtronic
• Neutral Sentiment: Value-investor comparisons with Agilent Technologies and proxy-recommendation coverage may attract attention, but neither provides a clear new earnings or fundamental catalyst for MDT. MDT vs. A: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Medtronic faces a potential injunction in its Applied Medical case. An adverse ruling could create operational or legal uncertainty and represents a risk ahead of earnings. Medtronic faces potential injunction in Applied Medical case
• Negative Sentiment: Reported insider activity showed eight sales and no purchases over the past six months, while estimated CEO compensation increased year over year. These signals could weigh modestly on sentiment, although they do not necessarily indicate a change in Medtronic’s fundamentals. Medtronic CEO 2026 Pay Revealed

Wall Street Analyst Weigh In

A number of research analysts recently commented on MDT shares. JPMorgan Chase & Co. decreased their price target on Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Robert W. Baird cut their price objective on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, June 4th. Sanford C. Bernstein reduced their price objective on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Mizuho decreased their target price on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday, June 3rd. Finally, Weiss Ratings cut shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Eighteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.83.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Trading Up 2.2%

Shares of MDT stock opened at $94.13 on Thursday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The stock’s fifty day moving average price is $83.88 and its two-hundred day moving average price is $86.08. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The company has a market cap of $120.49 billion, a PE ratio of 25.24, a P/E/G ratio of 2.47 and a beta of 0.55.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the previous year, the firm earned $1.62 EPS. Medtronic’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities analysts predict that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were given a $0.72 dividend. This is a boost from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date was Friday, June 26th. Medtronic’s dividend payout ratio (DPR) is presently 77.21%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).